[Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer:...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Context:

• Prostate cancer commonly metastasizes to bone, necessitating accurate assessment of bone lesions for tumor burden and treatment response.
• Castration-resistant prostate cancer (CRPC) signifies progression despite hormone reduction, often with distant metastasis.
• Standardized assessment of CRPC treatment effects using bone scintigraphy is crucial, as outlined by Prostate Cancer Working Group 3 (PCWG3) guidelines.

Purpose:

• To provide a clear overview of image acquisition and treatment response assessment for bone scintigraphy in metastatic CRPC.
• To facilitate practical implementation of PCWG3 guidelines for bone lesion evaluation.
• To enhance understanding of standardized bone lesion assessment in advanced prostate cancer.

Summary:

• Bone is the most frequent site of prostate cancer metastasis.
• Castration-resistant prostate cancer (CRPC) is defined by cancer progression despite hormone suppression.
• Bone scintigraphy is vital for evaluating bone metastases in CRPC, guided by PCWG3 standards.

Impact:

• Improved understanding and application of bone scintigraphy for CRPC management.
• Standardized evaluation of metastatic bone lesions, aiding treatment decisions.
• Enhanced assessment of tumor burden and treatment efficacy in advanced prostate cancer patients.